Verve Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €21.46M +18.4% -€402.48M +98.9% -1,875.2% -7.6 pp N/A N/A
    (estimated) €18.12M -4.5% -€202.36M -16.6% -1,116.5% +1.6 pp N/A N/A
    (estimated) €18.97M -4.0% -€242.68M +5.6% -1,279.3% -1.2 pp -€220.71M +3.1% -1,163.5% -0.80 pp
    (estimated) €19.76M -51.0% -€229.86M +17.8% -1,163.1% -6.8 pp -€214.11M -7.0% -1,083.4% -5.1 pp
    (estimated) €40.30M +44.4% -€195.05M +13.7% -484.0% +1.3 pp -€230.14M +73.2% -571.1% -0.95 pp
    €27.90M +175.0% -€171.49M -0.7% -614.6% +11 pp -€132.87M +9.8% -476.2% +7.2 pp
    €10.15M +505.8% -€172.67M +27.1% -1,701.5% +64 pp -€121.05M +28.6% -1,192.9% +44 pp
    €1.68M +∞% -€135.83M +32.7% -8,108.6% -81 pp -€94.16M +48.4% -5,620.8% -56 pp
    €0.00 +NaN% -€102.39M +160.5% N/A -€63.45M +130.9% N/A
    €0.00 +NaN% -€39.30M +139.5% N/A -€27.48M +470.1% N/A
    €0.00 -€16.41M N/A -€4.82M N/A

    Notifications